Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176713 | 0.95 | PTGER1 (0.61) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL12407580 | 0.93 | PTGER1 (0.53) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL12407575 | 0.93 | PTGER1 (0.57) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL12481532 | 0.91 | PTGER1 (0.51) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL2174544 | 0.91 | PTGER1 (0.54) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL12407581 | 0.91 | PTGER1 (0.51) | PTGER1THRBCA12CA1CA2 | |
| SCHEMBL13894263 | 0.89 | PTGER1 (0.54) | PTGER1THRBOXTRMEN1KMT2A | |
| SCHEMBL2174802 | 0.87 | PTGER1 (0.54) | PTGER1THRBOXTRMEN1KMT2A | |
| SCHEMBL12407255 | 0.86 | PTGER1 (0.64) | PTGER1THRBOXTR | |
| SCHEMBL12407469 | 0.86 | PTGER1 (0.60) | PTGER1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | claimed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | PTGER1 1/4885THRB 2988/4885CA12 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.